The study has been approved by the Brent Ethics Committee. It has also been approved for inclusion into the UKCRC portfolio. The conduct of the study is governed through an independent study steering committee and a data monitoring committee appointed by the NIHR Health Technology Assessment.
Study Steering Committee
Prof Bertie Squire, Consultant Infectious Disease Physician, University of Liverpool – Chair
Dr Sani Aliyu, Consultant in Infectious Disease and Microbiology, Addenbrooke’s University Hospital
Dr Stuart Baugh, Consultant Respiratory Physician, Goole Hospital
Prof Ibrahim Abubakar, Study Chief Investigator
Observers: Prof Francis Drobniewski, Prof Ajit Lalvani, Prof Jon Deeks
Data Monitoring Committee
Dr Ann Chapman, Consultant in Infectious Diseases (Chair)
Dr John Innes, Retired Consultant Chest Physician
Observer: Prof Jon Deeks
The UK Prognostic Study of the Interferon Gamma Release Assay for Tuberculosis (PREDICT)
Welcome to the website for the PREDICT study, which will look at the tests that are available for diagnosing people with tuberculosis, TB. This study is funded by the NIHR HTA Programme and coordinated by Public Health England. We are working in NHS sites, clinics, GP surgeries and community settings to investigate prognostic value of tests for latent tuberculosis infection.
TB is a disease which can take a long time to develop after a person is infected with the bacteria. The time between infection and becoming ill with symptoms of TB is called the latent period. During the latent period, some people manage to beat the infection and do not go on to have symptoms, but other people do go on to become ill. The tests that we have at the moment are not able to tell us who will become ill and who won’t. In this study we will be looking at some new tests that may help to do this so that we don’t treat people who will stay well, especially because some of the TB treatments have some side effects.
We have now completed the study. Our results will be published soon in the Lancet Infectious Diseases and in the NIHR HTA journal.
Our academic partners include
University College London
University of Birmingham
Queen Mary University of London